Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 857 posts found.

NICE recommends GSK’s Nucala for more asthma patients

December 18, 2020
Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab

NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …

News
nice_new_london_office_internal_3_web

NICE recommends Novartis’ Beovu for wet age-related macular degeneration

December 16, 2020
Research and Development NICE, Novartis, wet AMD Beovu

NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …

News

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

News

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …

News
astrazeneca_sign_sky

NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …

News
lilly_building_with_american_flag_web

NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …

News

NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura

November 12, 2020
Sales and Marketing NHS, NICE, Sanofi, pharma

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …

News
nice_reception_2

NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

News

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

News
nice_new_london_office_internal_3_web

NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia

October 30, 2020
Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide

Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …

News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

News
nice_new_london_office_internal_3_web

NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation

September 30, 2020
Research and Development, Sales and Marketing NHS, NICE, Rizmoic, Sandoz, UK

The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation …

News

Opdivo scores NICE recommendation in two non-small cell lung cancer indications

September 17, 2020
Sales and Marketing NICE, lung cancer, opdivo

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …

News
astrazeneca_sign_sky

NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications

September 11, 2020
Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso

NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …

News

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant

September 11, 2020
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid

It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024